Hydroxychloroquine and Azithromycin as Treatments for COVID-19

被引:0
|
作者
Ohe, Masashi [1 ]
Furuya, Ken [1 ]
Goudarzi, Houman [2 ,3 ]
机构
[1] JCHO Hokkaido Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ, Grad Fac Med, Sapporo, Hokkaido, Japan
来源
GAZI MEDICAL JOURNAL | 2020年 / 31卷 / 2A期
关键词
COVID-19; SARS-CoV-2; Hydroxychloroquine; Macrolide; Azithromycin;
D O I
10.12996/gmj.2020.82
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak that originated in late 2019 and continues to spread as of 2020 is taking a severe toll on human health and has been acknowledged as a worldwide pandemic. There have been no readily available vaccines or drugs that have been approved to combat the disease (COVID-19) as of yet. Chloroquine (CQ), a drug well-known for its effectiveness in treating malarial and autoimmune disease such as rheumatoid arthritis and lupus erythematosus, has exhibited a promising inhibitory effect for SARS-CoV-2. Hydroxychloroquine (HCQ), a more tolerable derivative of CQ, has also been shown to display potent activity against SARS-CoV-2. Macrolides (MACs) such as erythromycin, clarithromycin, and azithromycin (AZM) not only have the potential for anti-bacterial activity but also have immunomodulatory effects. Lately, the anti-viral effects of MACs have attracted considerable attention. Very recently, HCQ in combination with AZM treatment was reported to be effective for mild form of COVID-19. Because mild form of COVID-19 may take a turn for the worse, resulting in acute respiratory distress syndrome, or mild COVID-19 patients may infect surrounding people with COVID-19, patients should be treated with HCQ in combination with AZM.
引用
收藏
页码:337 / 338
页数:2
相关论文
共 50 条
  • [41] Hydroxychloroquine and azithromycin use in COVID-19 era and cardiovascular concerns: Current perspective
    Kapoor, Aditya
    Sahu, Ankit Kumar
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2021, 7 (01) : 78 - 82
  • [42] Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response
    Fiolet, Thibault
    Guihur, Anthony
    Rebeaud, Mathieu Edouard
    Mulot, Matthieu
    Peiffer-Smadja, Nathan
    Mahamat-Saleh, Yahya
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (01) : 138 - 140
  • [43] Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
    Abou Warda, Ahmed E.
    Tammam, Mahmoud
    El-Gazar, Rabab A.
    Sarhan, Rania M.
    Gaber, Sayed
    CURRENT DRUG SAFETY, 2022, 17 (02) : 143 - 151
  • [44] QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights
    Lopez-Medina, Ana I.
    Campos-Staffico, Alessandra M.
    Luzum, Jasmine A.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (10) : 2793 - 2794
  • [45] Hydroxychloroquine and COVID-19
    Sinha, Neeraj
    Balayla, Galit
    POSTGRADUATE MEDICAL JOURNAL, 2020, 96 (1139) : 550 - 555
  • [46] No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France"
    Lebeaux, David
    Revest, Matthieu
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 36
  • [47] Azithromycin and Covid-19
    不详
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2020, (166): : 384 - 384
  • [48] COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients
    Stewart, Mark
    Rodriguez-Watson, Carla
    Albayrak, Adem
    Asubonteng, Julius
    Belli, Andrew
    Brown, Thomas
    Cho, Kelly
    Das, Ritankar
    Eldridge, Elizabeth
    Gatto, Nicolle
    Gelman, Alice
    Gerlovin, Hanna
    Goldberg, Stuart L.
    Hansen, Eric
    Hirsch, Jonathan
    Ho, Yuk-Lam
    Ip, Andrew
    Izano, Monika
    Jones, Jason
    Justice, Amy C.
    Klesh, Reyna
    Kuranz, Seth
    Lam, Carson
    Mao, Qingqing
    Mataraso, Samson
    Mera, Robertino
    Posner, Daniel C.
    Rassen, Jeremy A.
    Siefkas, Anna
    Schrag, Andrew
    Tourassi, Georgia
    Weckstein, Andrew
    Wolf, Frank
    Bhat, Amar
    Winckler, Susan
    Sigal, Ellen, V
    Allen, Jeff
    PLOS ONE, 2021, 16 (03):
  • [49] Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial
    Abbas, Hassan M.
    Al-Jumaili, Ali Azeez
    Nassir, Kawthar F.
    Al-Obaidy, Muhammed Waheeb
    Al Jubouri, Adnan Mohammed
    Dakhil, Basim Dhawi
    Abdulelah, Mohammed Mahir
    Al Khames, Qutaiba Ahmed
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (04)
  • [50] Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin
    Chang, David
    Saleh, Moussa
    Gabriels, James
    Ismail, Haisam
    Goldner, Bruce
    Willner, Jonathan
    Beldner, Stuart
    Mitra, Raman
    John, Roy
    Epstein, Laurence M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (23) : 2992 - 2993